Clostridium difficile Infections - Pipeline Review, H1 2017

  • ID: 4245275
  • Report
  • 188 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • Absynth Biologics Ltd
  • AvidBiotics Corp
  • GangaGen Inc
  • Micropharm Ltd
  • Pfizer Inc
  • Serometrix LLC
  • MORE
Clostridium difficile Infections - Pipeline Review, H1 2017

Summary

Our latest Pharmaceutical and Healthcare disease pipeline guide Clostridium difficile Infections - Pipeline Review, H1 2017, provides an overview of the Clostridium difficile Infections (Infectious Disease) pipeline landscape.

Clostridium difficile infections are caused by Clostridium difficile, often called C. difficile or C. diff, a bacterium that can cause symptoms ranging from diarrhea to life-threatening inflammation of the colon. Symptoms of C. diff infection includes watery diarrhea, with abdominal pain or tenderness, loss of appetite, fever, blood or pus in the stool and weight loss. Risk factors are age, surgery of the gastrointestinal (GI) tract, a weakened immune system, kidney disease, use of drugs called proton-pump inhibitors, which lessen stomach acid and use of chemotherapy drugs. This condition may be controlled by the use of medication such as antibiotics and may be prevented by lifestyle modification.

Report Highlights

Our Pharmaceutical and Healthcare latest pipeline guide Clostridium difficile Infections - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Clostridium difficile Infections (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Clostridium difficile Infections (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Clostridium difficile Infections (Clostridium difficile Associated Disease) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 4, 9, 11, 29, 15 and 1 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 5 and 7 molecules, respectively.

Clostridium difficile Infections (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from our proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Clostridium difficile Infections (Infectious Disease).
- The pipeline guide reviews pipeline therapeutics for Clostridium difficile Infections (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Clostridium difficile Infections (Infectious Disease) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Clostridium difficile Infections (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Clostridium difficile Infections (Infectious Disease)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Clostridium difficile Infections (Infectious Disease).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Clostridium difficile Infections (Infectious Disease) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Absynth Biologics Ltd
  • AvidBiotics Corp
  • GangaGen Inc
  • Micropharm Ltd
  • Pfizer Inc
  • Serometrix LLC
  • MORE
List of Tables

List of Figures

Introduction

Report Coverage

Clostridium difficile Infections (Clostridium difficile Associated Disease) - Overview

Clostridium difficile Infections (Clostridium difficile Associated Disease) - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Clostridium difficile Infections (Clostridium difficile Associated Disease) - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Clostridium difficile Infections (Clostridium difficile Associated Disease) - Companies Involved in Therapeutics Development

Absynth Biologics Ltd

Actelion Ltd

AIMM Therapeutics BV

Akthelia Pharmaceuticals Ltd

AmpliPhi Biosciences Corp

Appili Therapeutics

Assembly Biosciences Inc

AvidBiotics Corp

C3J Therapeutics Inc

CaroGen Corp

Crestone Inc

Da Volterra SAS

Daiichi Sankyo Company Ltd

Evec Inc

GangaGen Inc

ImmunoBiology Ltd

Immuron Ltd

Inovio Pharmaceuticals Inc

Integrated BioTherapeutics Inc

Merck & Co Inc

MGB Biopharma Ltd

Microbiotix Inc

Micropharm Ltd

Miyarisan Pharmaceutical Company Ltd

Nabriva Therapeutics AG

Nanotherapeutics Inc

Novabiotics Ltd

NovoBiotic Pharmaceuticals LLC

Oragenics Inc

Otsuka Holdings Co Ltd

Pfizer Inc

Prokarium Ltd

Rebiotix Inc

Sanofi Pasteur SA

Second Genome Inc

Seres Therapeutics Inc

Serometrix LLC

Sorrento Therapeutics Inc

Summit Therapeutics Plc

Synthetic Biologics Inc

Valevia UK Ltd

Valneva SE

XBiotech Inc

Clostridium difficile Infections (Clostridium difficile Associated Disease) - Drug Profiles

ABCD-01 - Drug Profile

ABIM-101 - Drug Profile

AKT-10081 - Drug Profile

Antibodies for Enterocolitis - Drug Profile

Antibodies to Inhibit Toxin A and Toxin B for Clostridium difficile Infections - Drug Profile

AvR2-V10 - Drug Profile

Biologic for Clostridium difficile Infections - Drug Profile

Biologics for Clostridium Difficile Infections - Drug Profile

cadazolid - Drug Profile

CBM-588 - Drug Profile

CD-17DL - Drug Profile

Cdiff Snare - Drug Profile

clofazimine - Drug Profile

Clostridium difficile (virus like particle) vaccine - Drug Profile

Clostridium difficile vaccine - Drug Profile

Clostridium difficile vaccine - Drug Profile

Clostridium difficile vaccine - Drug Profile

Clostridium difficile vaccine - Drug Profile

clostridium difficile vaccine - Drug Profile

Clostridium difficile vaccine - Drug Profile

Clostridium difficile vaccine - Drug Profile

Clostridium difficile vaccine - Drug Profile

Clostridium difficile vaccine - Drug Profile

Clostridium difficile vaccine - Drug Profile

CP-101 - Drug Profile

CRS-3123 - Drug Profile

DAV-132 - Drug Profile

DiffiKil - Drug Profile

Drugs for Clostridium difficile Infections - Drug Profile

DS-2969 - Drug Profile

EV-029104 - Drug Profile

EV-029105A - Drug Profile

fidaxomicin - Drug Profile

FIN-403 - Drug Profile

IMM-529 - Drug Profile

INS-5010 - Drug Profile

MBX-500 - Drug Profile

MCB-3681 - Drug Profile

MCB-3837 - Drug Profile

metronidazole - Drug Profile

MGBBP-3 - Drug Profile

Monoclonal Antibodies for Clostridium difficile Infections - Drug Profile

Monoclonal Antibodies to Inhibit TcdA and TcdB for Clostridium Difficile and Staphylococcus Aureus Infections - Drug Profile

Monoclonal Antibody for Clostridium Difficile Infections - Drug Profile

Monoclonal Antibody for Clostridium Difficile Infections - Drug Profile

Monoclonal Antibody to Inhibit Clostridium difficile Toxin A and Toxin B for Clostridium Difficile Infections - Drug Profile

NP-432 - Drug Profile

OG-253 - Drug Profile

OG-716 - Drug Profile

OPS-2071 - Drug Profile

OraCAb - Drug Profile

P-100031 - Drug Profile

P-4A - Drug Profile

PF-06425090 - Drug Profile

PolyCAb - Drug Profile

Polymers for Clostridium difficile Infections and Candidiasis - Drug Profile

ramoplanin - Drug Profile

RBX-2660 - Drug Profile

RBX-7455 - Drug Profile

ribaxamase - Drug Profile

ridinilazole - Drug Profile

SER-109 - Drug Profile

SER-262 - Drug Profile

SHP-01 - Drug Profile

Small Molecule to Inhibit Guanine Riboswitches for MRSA and Clostridium Difficile Infections - Drug Profile

Small Molecules for Clostridium Difficile Infections - Drug Profile

Small Molecules for Clostridium Difficile Infections - Drug Profile

Small Molecules for Clostridium difficile Infections - Drug Profile

Small Molecules to Inhibit 23S rRNA for Clostridium difficile and Helicobacter pylori Infections - Drug Profile

Small Molecules to Inhibit CD Toxin A and Toxin B for Clostridium Difficile Infections - Drug Profile

Small Molecules to Inhibit DNA Synthesis for Infectious Diseases - Drug Profile

Small Molecules to Inhibit Dynamin for Clostridium Difficile Infections - Drug Profile

Small Molecules to Inhibit Metalloprotease for Clostridium difficile Infections - Drug Profile

Small Molecules to Inhibit Toxin A and Toxin B for Clostridium Difficile Infections - Drug Profile

SQ-641 - Drug Profile

SYN-006 - Drug Profile

SYN-007 - Drug Profile

TNP-2092 - Drug Profile

VAL-301 - Drug Profile

VE-303 - Drug Profile

VLA-84 - Drug Profile

Clostridium difficile Infections (Clostridium difficile Associated Disease) - Dormant Projects

Clostridium difficile Infections (Clostridium difficile Associated Disease) - Discontinued Products

Clostridium difficile Infections (Clostridium difficile Associated Disease) - Product Development Milestones

Featured News & Press Releases

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development for Clostridium difficile Infections (Clostridium difficile Associated Disease), H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..2), H1 2017

Number of Products under Development by Universities/Institutes, H1 2017

Products under Development by Companies, H1 2017

Products under Development by Companies, H1 2017 (Contd..1), H1 2017

Products under Development by Companies, H1 2017 (Contd..2), H1 2017

Products under Development by Companies, H1 2017 (Contd..3), H1 2017

Products under Development by Universities/Institutes, H1 2017

Number of Products by Stage and Target, H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017

Number of Products by Stage and Route of Administration, H1 2017

Number of Products by Stage and Molecule Type, H1 2017

Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by Absynth Biologics Ltd, H1 2017

Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by Actelion Ltd, H1 2017

Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by AIMM Therapeutics BV, H1 2017

Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by Akthelia Pharmaceuticals Ltd, H1 2017

Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by AmpliPhi Biosciences Corp, H1 2017

Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by Appili Therapeutics, H1 2017

Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by Assembly Biosciences Inc, H1 2017

Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by AvidBiotics Corp, H1 2017

Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by C3J Therapeutics Inc, H1 2017

Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by CaroGen Corp, H1 2017

Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by Crestone Inc, H1 2017

Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by Da Volterra SAS, H1 2017

Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by Daiichi Sankyo Company Ltd, H1 2017

Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by Evec Inc, H1 2017

Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by GangaGen Inc, H1 2017

Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by ImmunoBiology Ltd, H1 2017

Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by Immuron Ltd, H1 2017

Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by Inovio Pharmaceuticals Inc, H1 2017

Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by Integrated BioTherapeutics Inc, H1 2017

Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by Merck & Co Inc, H1 2017

Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by MGB Biopharma Ltd, H1 2017

Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by Microbiotix Inc, H1 2017

Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by Micropharm Ltd, H1 2017

Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by Miyarisan Pharmaceutical Company Ltd, H1 2017

Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by Nabriva Therapeutics AG, H1 2017

Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by Nanotherapeutics Inc, H1 2017

Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by Novabiotics Ltd, H1 2017

Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by NovoBiotic Pharmaceuticals LLC, H1 2017

Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by Oragenics Inc, H1 2017

Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by Otsuka Holdings Co Ltd, H1 2017

Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by Pfizer Inc, H1 2017

Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by Prokarium Ltd, H1 2017

Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by Rebiotix Inc, H1 2017

Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by Sanofi Pasteur SA, H1 2017

Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by Second Genome Inc, H1 2017

Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by Seres Therapeutics Inc, H1 2017

Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by Serometrix LLC, H1 2017

Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by Sorrento Therapeutics Inc, H1 2017

Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by Summit Therapeutics Plc, H1 2017

Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by Synthetic Biologics Inc, H1 2017

Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by Valevia UK Ltd, H1 2017

Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by Valneva SE, H1 2017

Clostridium difficile Infections (Clostridium difficile Associated Disease) - Pipeline by XBiotech Inc, H1 2017

Clostridium difficile Infections (Clostridium difficile Associated Disease) - Dormant Projects, H1 2017

Clostridium difficile Infections (Clostridium difficile Associated Disease) - Dormant Projects, H1 2017 (Contd..1), H1 2017

Clostridium difficile Infections (Clostridium difficile Associated Disease) - Discontinued Products, H1 2017

List of Figures

Number of Products under Development for Clostridium difficile Infections (Clostridium difficile Associated Disease), H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products under Development by Universities/Institutes, H1 2017

Number of Products by Top 10 Targets, H1 2017

Number of Products by Stage and Top 10 Targets, H1 2017

Number of Products by Top 10 Mechanism of Actions, H1 2017

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017

Number of Products by Routes of Administration, H1 2017

Number of Products by Stage and Routes of Administration, H1 2017

Number of Products by Top 10 Molecule Types, H1 2017

Number of Products by Stage and Top 10 Molecule Types, H1
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
Absynth Biologics Ltd
Actelion Ltd
AIMM Therapeutics BV
Akthelia Pharmaceuticals Ltd
AmpliPhi Biosciences Corp
Appili Therapeutics
Assembly Biosciences Inc
AvidBiotics Corp
C3J Therapeutics Inc
CaroGen Corp
Crestone Inc
Da Volterra SAS
Daiichi Sankyo Company Ltd
Evec Inc
GangaGen Inc
ImmunoBiology Ltd
Immuron Ltd
Inovio Pharmaceuticals Inc
Integrated BioTherapeutics Inc
Merck & Co Inc
MGB Biopharma Ltd
Microbiotix Inc
Micropharm Ltd
Miyarisan Pharmaceutical Company Ltd
Nabriva Therapeutics AG
Nanotherapeutics Inc
Novabiotics Ltd
NovoBiotic Pharmaceuticals LLC
Oragenics Inc
Otsuka Holdings Co Ltd
Pfizer Inc
Prokarium Ltd
Rebiotix Inc
Sanofi Pasteur SA
Second Genome Inc
Seres Therapeutics Inc
Serometrix LLC
Sorrento Therapeutics Inc
Summit Therapeutics Plc
Synthetic Biologics Inc
Valevia UK Ltd
Valneva SE
XBiotech Inc
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll